SCI Pharmtech Inc (4119) - Total Liabilities
Based on the latest financial reports, SCI Pharmtech Inc (4119) has total liabilities worth NT$1.54 Billion TWD (≈ $48.65 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SCI Pharmtech Inc - Total Liabilities Trend (2002–2025)
This chart illustrates how SCI Pharmtech Inc's total liabilities have evolved over time, based on quarterly financial data. See 4119 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
SCI Pharmtech Inc Competitors by Total Liabilities
The table below lists competitors of SCI Pharmtech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korea Air Svc
KO:005430
|
Korea | ₩143.98 Billion |
|
Shanghai Highly Group Co Ltd B
SHG:900910
|
China | $15.67 Billion |
|
Condor Energies Inc.
TO:CDR
|
Canada | CA$86.14 Million |
|
Enad Global 7 AB
ST:EG7
|
Sweden | Skr1.09 Billion |
|
Paloma Acquisition Corp I Class A Ordinary Shares
NASDAQ:PALO
|
USA | $6.82 Million |
|
Invicta
JSE:IVT
|
South Africa | ZAC4.15 Billion |
|
MIRC Electronics Limited
NSE:MIRCELECTR
|
India | Rs3.27 Billion |
|
Chesapeake Gold Corp.
V:CKG
|
Canada | CA$13.06 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down SCI Pharmtech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SCI Pharmtech Inc (4119) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SCI Pharmtech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SCI Pharmtech Inc (2002–2025)
The table below shows the annual total liabilities of SCI Pharmtech Inc from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$1.49 Billion ≈ $47.02 Million |
-13.43% |
| 2024-12-31 | NT$1.72 Billion ≈ $54.31 Million |
+8.36% |
| 2023-12-31 | NT$1.59 Billion ≈ $50.12 Million |
+19.49% |
| 2022-12-31 | NT$1.33 Billion ≈ $41.94 Million |
+53.15% |
| 2021-12-31 | NT$869.26 Million ≈ $27.39 Million |
-30.33% |
| 2020-12-31 | NT$1.25 Billion ≈ $39.31 Million |
+105.61% |
| 2019-12-31 | NT$606.84 Million ≈ $19.12 Million |
+4.84% |
| 2018-12-31 | NT$578.85 Million ≈ $18.24 Million |
+58.21% |
| 2017-12-31 | NT$365.88 Million ≈ $11.53 Million |
-23.68% |
| 2016-12-31 | NT$479.43 Million ≈ $15.10 Million |
-31.02% |
| 2015-12-31 | NT$695.02 Million ≈ $21.90 Million |
-30.12% |
| 2014-12-31 | NT$994.64 Million ≈ $31.34 Million |
+1.02% |
| 2013-12-31 | NT$984.62 Million ≈ $31.02 Million |
+206.62% |
| 2012-12-31 | NT$321.12 Million ≈ $10.12 Million |
-16.65% |
| 2011-12-31 | NT$385.26 Million ≈ $12.14 Million |
+3.18% |
| 2010-12-31 | NT$373.37 Million ≈ $11.76 Million |
+74.21% |
| 2009-12-31 | NT$214.32 Million ≈ $6.75 Million |
+12.71% |
| 2008-12-31 | NT$190.16 Million ≈ $5.99 Million |
+7.59% |
| 2007-12-31 | NT$176.74 Million ≈ $5.57 Million |
+86.14% |
| 2006-12-31 | NT$94.94 Million ≈ $2.99 Million |
-26.42% |
| 2004-12-31 | NT$129.03 Million ≈ $4.07 Million |
+25.28% |
| 2003-12-31 | NT$102.99 Million ≈ $3.24 Million |
-60.04% |
| 2002-12-31 | NT$257.76 Million ≈ $8.12 Million |
-- |
About SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more